Monday, Integra LifeSciences Holdings Corporation (NASDAQ:IART) reported first-quarter revenues of $368.9 million, down 3.1% Y/Y on a reported basis and 2.5% on an organic basis, beating the consensus of $361.96 million and the management guidance of $360 million to $365 million. Revenue increased by 1.6% on an organic basis, excluding Boston. Integra Lifesciences reported an adjusted EPS of $0.55, which is in line with the consensus and lower than $0.74 a year ago. The management had forecasted first-quarter adjusted EPS of $0.53-$0.57. The company reported adjusted gross margin of 64.4%, compared to 67.3% in the prior year. Adjusted EBITDA for the first quarter of 2024 was $71.8 million, ...